phenyl pyruvic acid | 46115-41-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: phenyl pyruvic acid
• 英文别名: Phenyloxalat；2-Oxo-2-phenoxyacetic acid
• CAS: 46115-41-7
• 化学式: C₈H₆O₄
• 分子量: 166.133
• InChiKey: YVWNBNDYTKPZFP-UHFFFAOYSA-N

物化性质

• 沸点：
  306.0±25.0 °C(Predicted)
• 密度：
  1.365±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  phenyl pyruvic acid 在 水 、 对甲苯磺酸 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 20.0h， 生成 5-氯-3-苯基-1H-吲哚-2-羧酸
  参考文献：
  名称：

  Design, synthesis and pharmacophoric model building of new 3-alkoxymethyl/3-phenyl indole-2-carboxamides with potential antiproliferative activity

  摘要：

  Novel 3‐alkoxymethyl/3‐phenyl indole‐2‐carboxamide derivatives were synthesized and evaluated for their anticancer activity. Most of the tested compounds showed moderate to excellent activity against the tested cell lines (MCF7 and HCT116). 3‐Phenyl substitution on indole with p‐piperidinyl phenethyl 24a and p‐dimethylamino phenethyl 24c exhibited anticancer activity against MCF7 with IC50 of 0.13 and 0.14 μm, respectively. Further mechanistic study of the most active compounds through their action on cell cycle showed disturbance in cell cycle progression and cell cycle arrest. For future development of this series of compounds, pharmacophore study was conducted which indicated that the enhancement of the activity could be achieved through the addition of acceptor or donating groups to the already‐present indole nucleus.

  DOI：

  10.1111/cbdd.12928

文献信息

• Plasminogen Activator Inhibitor-1 Inhibitor
  申请人：Miyata Toshio

  公开号：US20120022080A1

  公开（公告）日：2012-01-26

  The present invention provides a novel compound having plasminogen activator inhibitor-1 inhibitory activity, and an inhibitor of PAI-1 comprising the compound as an active ingredient. The present invention also provides a pharmaceutical composition having an inhibitory action on PAI-1 activity and being efficacious in the prevention and treatment of various diseases whose onset is associated with PAI-1 activity.

  本发明提供了一种具有纤溶酶原激活物抑制剂-1抑制活性的新化合物，以及包括该化合物作为活性成分的PAI-1抑制剂。本发明还提供了一种对PAI-1活性具有抑制作用且在预防和治疗与PAI-1活性相关的各种疾病方面有效的药物组合物。
• [EN] PROCESS FOR THE SYNTHESIS OF (5a,17ß)-N-[(2,5-BIS(TRIFLUOROMETHYL)-PHENYL]-3-OXO-4-AZA-5-ANDROST-1-ENE-17-CARBOXAMIDE<br/>[FR] PROCÉDÉ DE SYNTHÈSE DU (5?,17?)-N-[(2,5-BIS(TRIFLUOROMÉTHYL)-PHÉNYL]-3-OXO-4-AZA-5-ANDROST-1-ÈNE-17-CARBOXAMIDE
  申请人：RICHTER GEDEON NYRT

  公开号：WO2013001322A1

  公开（公告）日：2013-01-03

  The synthesis consists of reaction steps as follows: oxidizing the α,β-unsaturated ketone system of ring "A" of pregn-4-ene-3,20-dion- of formula (II) with sodium metaperiodate in tert-butanol in the presence of potassium permanganate and alkali metal carbonate, reacting the obtained 3,5-seco acid with an ester of chloroformic acid in the presence of tertier organic base below 0°C, reacting the obtained new compound after isolation or without isolation with ammonia or ammonium acetate, cyclization of the resulting carboxamides with an acid, cathalytic hydrogenating the obtained ene lactame, and oxidizing the side chain at position 17 of the obtained pregnane compound with an alkali metal hypobromide in aqueous dioxane below 10°C. Thereafter on one hand the obtained (5α,17β)-3-oxo-4-aza-5-androstane-17-carboxylic acid is reacted with chloroformic acid ester, the obtained new compound is reacted with 2,5-bis(trifluoromethyl)-aniline in the presence of a Lewis acid, the obtained amide is reacted with trimethyl chlorosilane in inert atmosphere in the presence of Ν,Ν,Ν',Ν'-tetramethyl-ethylendiamine, then en excess iodine is added to the reaction mixture and the product of the iodination reaction is crystallized from acetonitrile, then the obtained 2-iodo-3-oxo-4-aza-17β-carboxamide is reacted with potassium tert-butylate to furnish final product. On the other hand, (5α,17β)-3-oxo-4-aza-5-androstane-17-carboxylic acid is transformed into methylester by known method, this latter is transformed into methyl (2α,5α,17β)-2-iodo-3-oxo-4-aza-5-androstane-17-carboxylate according to known method, the obtained compound is reacted with potassium-tert-butylate, the obtained (5α,17β)-3-oxo-4-aza-5-androst-1-ene-17-carboxylic acid is reacted with an ester of chloroformic acid, then the obtained new compound is coupled with 2,5-bis(trifluoromethyl)-aniline in the presence of a Lewis acid catalyst to gain final product.

  合成包括以下反应步骤：在三氢甲苯醇中存在高锰酸钾和碱金属碳酸盐的情况下，氧化孕甾-4-烯-3,20-二酮环“A”的α，β-不饱和酮系统，用亚碘酸钠，将得到的3,5-内酰胺与氯甲酸酯在0°C以下的温度下在三级有机碱的存在下反应，将得到的新化合物在隔离或不隔离的情况下与氨或乙酸铵反应，将得到的羧酰胺与酸环化，催化氢化得到的烯内酯胺，用水合二氧六环中的碱性次溴酸盐氧化得到的孕烷化合物17位侧链。然后，一方面得到的(5α,17β)-3-氧代-4-氮代-5-雄烷-17-羧酸与氯甲酸酯反应，得到的新化合物与2,5-双(三氟甲基)-苯胺在Lewis酸的存在下反应，得到的酰胺在惰性气氛中与三甲基氯硅烷在Ν，Ν，Ν'，Ν'-四甲基-乙二胺的存在下反应，然后向反应混合物中加入过量碘，并从乙腈中结晶得到碘化反应的产物，然后得到的2-碘代-3-氧代-4-氮代-17β-羧酰胺与叔丁基钾反应以得到最终产物。另一方面，(5α,17β)-3-氧代-4-氮代-5-雄烷-17-羧酸通过已知方法转化为甲酯，这后者通过已知方法转化为甲基(2α,5α,17β)-2-碘代-3-氧代-4-氮代-5-雄烷-17-羧酸酯，得到的化合物与叔丁基钾反应，得到的(5α,17β)-3-氧代-4-氮代-5-雄-1-烯-17-羧酸与氯甲酸酯反应，然后得到的新化合物在Lewis酸催化剂的存在下与2,5-双(三氟甲基)-苯胺偶联以获得最终产物。
• [EN] 2,3-DIHYDROBENZO(1,4) DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEM DISEASES<br/>[FR] DÉRIVÉS DE 2,3-DIHYDROBENZO[1,4] DIOXIN-2-YLMÉTHYLE UTILISÉS EN TANT QU'ANTAGONISTES DES ALPHA2C POUR TRAITER DES MALADIES DES SYSTÈMES NERVEUX PÉRIPHÉRIQUE ET CENTRAL
  申请人：ORION CORP

  公开号：WO2009013390A1

  公开（公告）日：2009-01-29

  Compounds of formula (I), wherein X, Z, R1-R4, and m are as defined in the claims, exhibit alpha2C antagonistic activity and are thus useful for the treatment of diseases and conditions of the peripheric system and the central nervous system (CNS).

  式(I)的化合物，其中X、Z、R1-R4和m如权利要求中所定义，具有α2C拮抗活性，因此可用于治疗外周系统和中枢神经系统（CNS）的疾病和症状。
• [EN] SOLVENT-FREE PROCESS FOR THE PREPARATION OF DIKETOPYRROLOPYRROLE DERIVATIVES<br/>[FR] PROCEDE DE PREPARATION SANS SOLVANT DE DERIVES DICETOPYRROLOPYRROLIQUES
  申请人：MCA TECHNOLOGIES GMBH

  公开号：WO2004076456A1

  公开（公告）日：2004-09-10

  The present application relates to compounds of formula A(D)X(E)y, (I), compounds of formula (III), compounds of formula (X), as well as processes for the preparation thereof, processes where the compounds (I) are converted to pigments of formula (II) and the use of the compounds (I).

  本申请涉及到化合物的公式A(D)X(E)y（I），化合物的公式（III），化合物的公式（X），以及其制备方法，其中化合物（I）被转化为公式（II）的颜料的方法和化合物（I）的使用。
• ONIUM SALT, CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS
  申请人：Shin-Etsu Chemical Co., Ltd.

  公开号：US20220127225A1

  公开（公告）日：2022-04-28

  An onium salt having formula (1) serving as an acid diffusion inhibitor and a chemically amplified resist composition comprising the acid diffusion inhibitor are provided. When processed by lithography, the resist composition forms a pattern having minimal defects and excellent lithography performance factors such as CDU, LWR and DOF.

  提供一种化学式为(1)的盐类，作为酸扩散抑制剂，并提供一种化学增强型光刻胶组合物，其中包括该酸扩散抑制剂。当通过光刻技术进行加工时，该光刻胶组合物形成的图案具有最小的缺陷和出色的光刻性能因子，如CDU、LWR和DOF。